# Day One Biopharmaceuticals (DAWN) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/DAWN
## Company Profile
- Ticker: DAWN
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 21.53 USD
- Market cap: 2220651291.81 USD
- Last updated: 2026-04-22
## Business Overview
### Pediatric and Rare Oncology
Day One Biopharmaceuticals develops targeted therapies for cancers affecting children and adults. The company was founded around pediatric oncology and is expanding into additional rare tumor types.
### OJEMDA
OJEMDA is a type II RAF inhibitor approved for relapsed or refractory pediatric low-grade glioma with an activating RAF alteration. It provides Day One’s commercial foundation and is being studied in the frontline setting.
### FIREFLY Program
FIREFLY-1 supported approval and continues to provide long-term durability data. FIREFLY-2 is a pivotal Phase 3 trial evaluating OJEMDA in newly diagnosed pediatric low-grade glioma.
### Emi-Le
Emi-Le is a B7-H4-directed antibody-drug conjugate acquired with Mersana Therapeutics. It is in Phase 1 development for adenoid cystic carcinoma and broadens Day One into rare adult cancers.
### DAY301
DAY301 is a PTK7-targeted antibody-drug conjugate in Phase 1a dose escalation. The program adds a second ADC mechanism and another opportunity beyond the OJEMDA franchise.
## Why The Stock Is Moving

Current closing-price context is not available for DAWN.

## Future Catalysts

- Completion of enrollment in the Phase 3 FIREFLY-2 trial expected in the first half of 2026.
- Updated Phase 1 Emi-Le data expected in mid-2026.
- Initial Phase 1a DAY301 data and program update expected in the second half of 2026.

## Recent News
- 2026-03-06 13:30 EST — [Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio](https://biopharmsignal.com/news/DAWN/servier-and-day-one-biopharmaceuticals-announce-acquisition-to-expand-servier-s-rare-oncology-portfolio) — Source: Day One Biopharmaceuticals
- 2026-02-24 21:00 EST — [Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance](https://biopharmsignal.com/news/DAWN/day-one-reports-fourth-quarter-and-full-year-2025-financial-results-and-reaffirms-2026-outlook-and-revenue-guidance) — Source: Day One Biopharmaceuticals
- 2026-02-10 13:30 EST — [Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026](https://biopharmsignal.com/news/DAWN/day-one-to-report-fourth-quarter-and-full-year-2025-financial-results-tuesday-february-24-2026) — Source: Day One Biopharmaceuticals
- 2026-01-11 22:00 EST — [Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance](https://biopharmsignal.com/news/DAWN/day-one-announces-preliminary-2025-ojemdatm-net-product-revenue-and-provides-2026-net-product-revenue-guidance) — Source: Day One Biopharmaceuticals
- 2026-01-06 14:02 EST — [Day One Completes Acquisition of Mersana Therapeutics](https://biopharmsignal.com/news/DAWN/day-one-completes-acquisition-of-mersana-therapeutics) — Source: Day One Biopharmaceuticals